The company said, “The Long-Range Plan builds upon the successful execution of the previous three years. NeoGenomics (NEO) intends to achieve the following: 12-13% revenue growth annually, including NGS growth of ~25% per year; gross margin expansion of 100-150 bps per year; adjusted EBITDA improvement of 250-300 bps per year; positive cash flow from operations in 2025 and beyond and serving more than 1M patients annually by 2028 and beyond.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO: